In colorectal cancer (CRC), hypomethylation of the Hes1 promoter region results in its significant upregulation, and its high expression status is closely associated with tumor malignancy, lymph node metastasis, and advanced clinical stages, indicating a worse prognosis for CRC patients with Hes1 hypomethylation (125). This evidence concerns the gene HES1 and metastatic malignant neoplasm in the lymph nodes.